

¹⁵ Center for Cell and Gene Therapy, The Texas Children's Cancer Center, and Department of Ophthalmology, Baylor College of Medicine, Houston, Texas.

Presented in part at: the International Society of Ocular Oncology meeting, March 24–28, 2017, Sydney, Australia.

Financial Disclosure(s):

The author(s) have made the following disclosure(s): A.H.S.: Consultant – Castle Biosciences Inc.

D.S.G.: Travel compensation and Co–principal investigator: Children's Oncology Group trial; Travel compensation and consultant – American Board of Ophthalmology; Consultant – AbbVie, Aura Biosciences, American Society of Clinical Oncology, Castle Biosciences; Grants – Housemann/Wilkins Foundation and Lois Kuss Fund for Glaucoma Research.

B.L.G.: Unpaid Medical Director of Ocular Oncology at Impact Genetics; Employed – Hospital for Sick Children; Expert testimony – legal cases; Grants pending – Retina Society; Travel expenses – SickKids, and reports a pension.

B.P.M.: Consultant to, holds stock in, and receives travel expenses – Aura Biosciences.

S.E.P.: Member of the Scientific Advisory Board – Baylor Miraca Genetics Laboratories; Grants pending – National Institutes of Health; Royalties – Antibody Users; Travel expenses – American Association of Cancer Research.

P.C.-B.: Employed – Houston Methodist Physician Organization; Grants pending – NASA; Payment for lectures – UT Houston Medical School Ophthalmology; Travel expenses – Children's Oncology Group.

Supported by a Lloyd Research Endowment Faculty Grant (A.H.S.) and by an unrestricted departmental grant from Research to Prevent Blindness (New York, NY).

HUMAN SUBJECTS: This study does not include human subjects/tissues.

Author Contributions:

Conception and design: Skalet, Gombos, Gallie, Kim, Shields, Marr, Plon, Chévez-Barrios

Data collection: Skalet, Gombos, Gallie, Kim, Shields, Marr, Plon, Chévez-Barrios

Analysis and interpretation: Skalet, Gombos, Gallie, Kim, Shields, Marr, Plon, Chévez-Barrios

Obtained funding: Not applicable

Overall responsibility: Skalet, Gombos, Gallie, Kim, Shields, Marr, Plon, Chévez-Barrios


Abbreviations and Acronyms:

AAOOP = American Association of Ophthalmic Oncologists and Pathologists.

Correspondence:

Patricia Chévez-Barrios, MD, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, 6565 Fannin Street, M227, Houston, TX 77030. E-mail: pchevez-barrios@houstonmethodist.org.

Pictures & Perspectives



Unilateral Double Optic Nerve Head Pits

Color fundus photograph of 2 temporal pits within the left optic nerve head of a healthy 29-year-old woman with 20/20 Snellen equivalent visual acuity and normal visual fields (Fig 1A). En face OCT angiography (AngioVue; Optovue) of the optic nerve demonstrating vascular flow within the pits (Fig 1B). Infrared photo (Fig 1C) of the optic nerve clearly defines the pits. The *green line* denotes the orientation of the scan shown in Figure 1D. High-resolution OCT line scan (Spectralis; Heidelberg Engineering, Germany) through both pits (Fig 1D). (Magnified version of Fig 1A–D is available online at www.aajournal.org.)

ERIN A. BOESE, MD^{1,2}

DAVID HUANG, MD, PhD¹

SHANDIZ TEHRANI, MD, PhD¹

¹Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon; ²Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan

Footnotes and Financial Disclosures

Financial Disclosure(s):

Unrestricted grant from Research to Prevent Blindness; NIH Grants: R01 EY023285, UL1TR000128, and P30 EY010572; The Antonio Champalimaud Vision Award; and Heed Ophthalmic Foundation.